Risk topic

Pandemics

47 of 1505 companies added a paragraph in Risk Factors that uses one of these words: pandemic, COVID, epidemic, outbreak. The paragraph is in the latest 10-K and nothing like it was in the one before. It counts text; it does not say how serious a risk is. Words in capitals only (such as AI) must be in capitals.

By sector

Sector is the SEC's industry description of the company. The bar is the share of that sector's companies compared; each count opens that sector's quotes below.

54 paragraphs · Pharmaceutical Preparations show all sectors

ROIV Roivant Sciences Ltd. · Pharmaceutical Preparations

In February 2022, Roivant’s subsidiary GSG and Roivant’s affiliate Arbutus filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna and an affiliate seeking damages for infringement of certain patents, including U.S. Patent Nos. 8,492,359, 9,364,435, 9,504,651 and 11,141,378, in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19 (the “Moderna Action”). In 2025, GSG and Arbutus filed five international lawsuits against Moderna targeting alleged infringing activity with respect to Moderna’s vaccine for COVID-19 in 30 countries (the “Moderna International Cases”). On March 3, 2026, GSG and, solely for certain purposes, Genevant, and Arbutus entered into a settlement agreement with Moderna Inc. and Moderna TX, Inc. (the “Settlement Agreement”) to resolve the Moderna Action and the Moderna International Cases. Under the Settlement Agreement, Moderna agreed to make a $950 million noncontingent lump sum payment to GSG and Arbutus on or before July 8, 2026. In addition, as described in more detail below, Moderna agreed to make an additional contingent lump sum payment of up to $1.3 billion (the “Contingent Payment”) to GSG and Arbutus, depending on the outcome of Moderna’s appeal of the District Court’s rejection of Moderna’s affirmative defense under 28 U.S.C. § 1498 (“§ 1498”). In March 2026, Moderna filed a notice of its appeal (the “§ 1498 Appeal”) with the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”). Briefing of the § 1498 Appeal is expected to be completed in July 2026, with oral arguments before the Federal Circuit expected to take place in 2027.

Read in the 10-K filed May 20, 2026
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.